Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial

Fineline Cube Apr 29, 2026
Company Drug

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Fineline Cube Apr 29, 2026
Company Deals

Kunshan Yiyuan Medical Technology Secures Over RMB 100 Million in Series B Financing

Fineline Cube Aug 4, 2023

Kunshan Yiyuan Medical Technology Co., Ltd (Medical Source), a company in China that specializes in...

Company Deals

HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max

Fineline Cube Aug 4, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm...

Company

Novartis China’s Business Growth Lead Zhu Jiakang Departs for Personal Reasons

Fineline Cube Aug 4, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has seen the departure of Zhu Jiakang, who led...

Company

BeiGene’s Q2 2023 Financial Report Highlights 81.8% YOY Product Revenue Growth

Fineline Cube Aug 3, 2023

China-based biotech company BeiGene (SHA: 688235, HKG: 6160, NASDAQ: BGNE) has released its financial report...

Legal / IP Policy / Regulatory

National Health Commission’s Anti-Corruption Drive Impacts China’s Pharmaceutical Sector

Fineline Cube Aug 3, 2023

An anti-corruption crackdown announced by the National Health Commission (NHC) at the end of July...

Company Medical Device

Our United Corporation’s Linear Accelerator Approved as Innovative Medical Device by NMPA

Fineline Cube Aug 3, 2023

Xi’an-based Our United Corporation has announced that its medical electronic linear accelerator has been approved...

Company Drug

CORXEL Gets CDE Approval for Phase III Presbyopia Trials of LNZ100 and LNZ101

Fineline Cube Aug 3, 2023

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has announced that...

Company Deals

Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Partners with Eyebright Medical Technology

Fineline Cube Aug 3, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has entered...

Company Deals

BeiGene and Bristol-Myers Squibb/Celgene Settle Partnership, Termination Set for 2023

Fineline Cube Aug 3, 2023

BeiGene (NASDAQ: BGNE) has announced a settlement and termination agreement with US firm Bristol-Myers Squibb/Celgene...

Company Medical Device

Suzhou Jiecheng Medical Secures FDA BDD for Transvascular Aortic Valve Treatment

Fineline Cube Aug 3, 2023

Suzhou Jiecheng Medical Technology Co., Ltd has announced that it has obtained Breakthrough Devices Designation...

Company Drug

ABM Therapeutics’ ABM-1310 Earns Orphan Drug Designation for BRAF V600 Mutant Glioblastoma

Fineline Cube Aug 3, 2023

Shanghai-based ABM Therapeutics Inc. has announced that it has received Orphan Drug Designation (ODD) from...

Company Deals

Huaboron Neutron Technology Secures Over RMB 100 Million in Angel Financing for BNCT System

Fineline Cube Aug 3, 2023

Huaboron Neutron Technology (Hangzhou) Co., Ltd (HBNCT) has reportedly secured more than RMB 100 million...

Company Deals

ICE Bioscience Secures Series B+ Financing to Boost Integration Capabilities

Fineline Cube Aug 3, 2023

Beijing-based Contract Research Organization (CRO) ICE Bioscience has reportedly raised close to RMB 100 million...

Company Drug

Sumitomo Pharma and Otsuka’s Ulotaront Fails to Meet Primary Endpoint in Schizophrenia Trials

Fineline Cube Aug 3, 2023

Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) and Otsuka Pharmaceutical Co., Ltd (FRA: OS1) have...

Company

Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials

Fineline Cube Aug 3, 2023

Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) has released its financial results for...

Company Deals

Biogen Inc. to Acquire Reata Pharmaceuticals in $7.3 Billion Deal

Fineline Cube Aug 2, 2023

US-based Biogen Inc., (NASDAQ: BIIB) has announced that it has reached an agreement to fully...

Company

Pfizer Inc. Reports Q2 2023 Revenues, Signals Shift Beyond COVID-19 Products

Fineline Cube Aug 2, 2023

US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the second...

Company Deals

EQRx Inc. to be Acquired by Revolution Medicines in All-Stock Transaction

Fineline Cube Aug 2, 2023

US-based EQRx Inc. (NASDAQ: EQRX) has revealed that a definitive agreement has been signed for...

Company Deals

GSK Partners with Zuellig Pharma for Vaccine Distribution and Cold-Chain Management in Asia-Pacific

Fineline Cube Aug 2, 2023

GlaxoSmithKline (GSK; NYSE: GSK), a leading global vaccine manufacturer, has signed an agreement with Philippines-based...

Company Drug

Luye Pharma’s Parkinson’s Disease Treatment LY03003 Receives NMPA Review Acceptance

Fineline Cube Aug 2, 2023

Luye Pharma Group (HKG: 2186) has announced that the National Medical Products Administration (NMPA) has...

Posts pagination

1 … 486 487 488 … 659

Recent updates

  • Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed
  • Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion
  • Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement
  • Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets
  • Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed

Company

Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion

Company

Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.